RNA-driven phase separation from cells to SARS
Biomolecular condensation is a mechanism for controlling cell organization. Many condensates are rich in nuclei acids such as RNA. The role of specific RNA sequences and structures in promoting the molecular identity of condensates formed for cell polarity and division and by the SARS CoV-2 virus will be discussed.
SARC-CoV-2 modeling: What have we learned from this pandemic about how (not) to model disease spread?
The SARS-CoV-2 pandemic is awash in data, including daily, spatially-resolved COVID case data, virus sequence data, patients `omics data, and mobility data. Journals are now also awash in studies that make use of quantitative modeling approaches to gain insight into the geographic spread of SARS-CoV-2 and its temporal dynamics, as well as studies that predict the impact of control strategies on SARS-CoV-2 circulation. Some, but by no means all, of these studies are informed by the massive amounts of available data. Some, but by no means all, of these studies have been useful — in that their predictions revealed something beyond simple back of the envelope calculations. To summarize some of these findings, in this symposium, we will address questions such as: What do we want from models of disease spread? What can and should be predicted? Which data are the most useful for predictions? When do we need mechanistic models? What have we learned about how to model disease spread from unmet and/or conflicting predictions? The workshop speakers will explore these questions from different perspectives on what data need to be considered and how models can be evaluated. As at other TMLS workshops, each speaker will deliver a 10-minute talk with ample time set aside for moderated questions/discussion. We expect the talks to be provocative and bold, while respecting different perspectives.
Lab-on-a-chip and diagnostic tools for COVID-19
The SARS-CoV-2 virus has rapidly evolved into a pandemic that is threatening public health, economics, and quality of life worldwide. The gold-standard for testing individuals for COVID-19 is using traditional RT-qPCR, which is expensive and can take up to several hours. Expanding surveillance across a global scale will call for new strategies and tests that are inexpensive, require minimal reagents, decrease assay time, and allow for simple point-of-care (POC) monitoring without need of trained personnel and with quick turnaround time. To expand the speed of COVID-19 surveillance, we are working on a point-of-care microfluidic chip to enable significantly faster and easier testing. This is based upon digital drop loop-mediated isothermal amplification that will allow for rapid testing of large populations at a reasonable cost. The device will employ a nucleic-acid based test called reverse transcriptase LAMP (RT- LAMP) that operates at a temperature of 60-65°C. RT-LAMP removes the bottleneck of thermal cycling and high temperatures required by traditional RT-qPCR thermocycling. The simplicity, speed, and sensitivity will enable early treatment and response to infection.